

Miltenyi Biotec

Reference list

CliniMACS Prodigy® T Cell Transduction

Clinical study results – patient treatment with CAR T cell products

Shah, N. N. *et al.* (2025) Phase I/II study of adaptive manufactured lentiviral anti-CD20/anti-CD19 chimeric antigen receptor T cells for relapsed, refractory mantle cell lymphoma. J. Clin. Oncol. 43: 2285–2295.
https://doi.org/10.1200/JCO-24-02158

Palani, H. K. *et al.* (2025) Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial. Mol. Ther. Oncol. 33: 200977.
https://doi.org/10.1016/j.omton.2025.200977

Ghobadi, A. *et al.* (2025) Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: A dual institution, phase 1 trial. EClinicalMedicine 81: 103138.
https://doi.org/10.1016/j.eclinm.2025.103138

Del Bufalo, F. *et al.* (2025) Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse. Blood Adv. 2025016181.
https://doi.org/10.1182/bloodadvances.2025016181

Mougiakakos, D. *et al.* (2025) Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders. Cytotherapy 27: 236–246.
https://doi.org/10.1016/j.jcyt.2024.09.008

Luanpitpong, S. *et al.* (2024) Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand. Mol. Ther. Oncol. 32: 200889.
https://doi.org/10.1016/j.omton.2024.200889

Aleksandrova, K. *et al.* (2024) Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma. Front. Immunol. 15: 1328368.
https://doi.org/10.3389/fimmu.2024.1328368

Zhang, Y. *et al.* (2023) Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: A first-in-human study. Mol. Cancer 22: 200.
https://doi.org/10.1186/s12943-023-01886-9

Oliver-Caldés, A. *et al.* (2023) Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): A single-arm, multicentre, academic pilot study. Lancet Oncol. 24: 913–924.
https://doi.org/10.1016/S1470-2045(23)00222-X

Chiesa, R. *et al.* (2023) Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389: 899–910.
https://doi.org/10.1056/NEJMoa2300709

Del Bufalo, F. *et al.* (2023) Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL. Blood 142: 146–157.
https://doi.org/10.1182/blood.2023020023

Ottaviano, G. *et al.* (2022) Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. Sci. Transl. Med. 14: eabq3010.
https://doi.org/10.1126/scitranslmed.abq3010

Kekre, N. *et al.* (2022) CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. Front. Immunol. 13: 1074740.
https://doi.org/10.3389/fimmu.2022.1074740

Foy, S. *et al.* (2022) Non-viral precision T cell receptor replacement for personalized cell therapy. Nature 615: 687–696.
https://doi.org/10.1038/s41586-022-05531-1

Mackensen, A. *et al.* (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Med. 28: 2124–2132.
https://doi.org/10.1038/s41591-022-02017-5

Spiegel, J. Y. *et al.* (2021) CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27: 1419–1431. *https://doi.org/10.1038/s41591-021-01436-0*

Ortíz-Maldonado, V. *et al.* (2021) CART19-BE-01: A multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed/ refractory malignancies. Mol. Ther. 29: 636–644. *https://doi.org/10.1016/j.ymthe.2020.09.027*

Mougiakakos, D. *et al.* (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385: 567–569. *https://www.doi.org/10.1056/NEJMc2107725*

Maschan, M. *et al.* (2021) Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat. commun. 12: 7200. *https://doi.org/10.1038/s41467-021-27312-6*

Jackson, Z. *et al.* (2020) Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma. Front. Immunol. 11: 1941. *https://doi.org/10.3389/fimmu.2020.01941*

Shah, N. N. *et al.* (2020) Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial. Nat. Med. 26: 1569–1575. *https://doi.org/10.1038/s41591-020-1081-3*

Castella, M. *et al.* (2020) Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: Experience from an academic phase I clinical trial. Front. Immunol. 11: 482. *https://doi.org/10.3389/fimmu.2020.00482*

Molostova, O. *et al.* (2019) Local manufacture of CD19 CAR-T cells using an automated closed-system: Robust manufacturing and high clinical efficacy with low toxicities. Blood 134: 2625. *https://doi.org/10.1182/blood-2019-130370*

Technical performance – manufacturing feasibility, CAR T cell functionality, and preclinical data

Salazar-Riojas, R. *et al.* (2025) Decentralized point-of-care manufacturing of CD19 chimeric antigen receptor T cells in Mexico. JCO Glob. Oncol. 11: e2400581. *https://doi.org/10.1200/GO-24-00581*

von Jutrzenka-Trzebiatowski, A. *et al.* (2025) CliniMACS Prodigy manufacturing of switchable, AND-gate CAR T cells. Int. J. Mol. Sci. 26: 5024. *https://doi.org/10.3390/ijms26115024*

Gupta, D. and Shaz, B. (2025) Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility. J. Transl. Med. 23: 507. *https://doi.org/10.1186/s12967-025-06400-x*

Szabo, D. *et al.* (2024) Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel. RMD Open 10: e004727. *https://doi.org/10.1136/rmdopen-2024-004727*

Song, H. W. *et al.* (2024) CAR-T cell expansion platforms yield distinct T cell differentiation states. Cytotherapy 26: 757–768. *https://doi.org/10.1016/j.jcyt.2024.03.003*

Phely, L. *et al.* (2024) Allogeneic CD19/CD22 CAR T-cell therapy for B-cell acute lymphoblastic leukemia. JAMA Oncol. 10: 821–824. *https://doi.org/10.1001/jamaoncol.2024.0473*

Müller, F. *et al.* (2024) CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N. Engl. J. Med. 390: 687–700. *https://doi.org/10.1056/NEJMoa2308917*

Malakhova, E. *et al.* (2024) Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration. Cytotherapy 26: 567–578. *https://doi.org/10.1016/j.jcyt.2024.02.025*

Jiang, G. *et al.* (2024) *In vitro* functionality and endurance of GMP-compliant point-of-care BCMA.CAR-T cells at different timepoints of cryopreservation. Int. J. Mol. Sci. 25: 1394. *https://doi.org/10.3390/ijms25031394*

Francis, N. *et al.* (2023) Development of an automated manufacturing process for large-scale production of autologous T cell therapies. Mol. Ther. Methods Clin. Dev. 31: 101114. *https://doi.org/10.1016/j.omtm.2023.101114*

Fischer-Riepe, L. *et al.* (2024) Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers. Clin. Cancer Res. 30: 3564–3577. *https://doi.org/10.1158/1078-0432.CCR-23-3157*

Dias, J. *et al.* (2024) CAR-T cell manufacturing landscape-Lessons from the past decade and considerations for early clinical development. Mol. Ther. Methods Clin. Dev. 32: 101250. *https://doi.org/10.1016/j.omtm.2024.101250*

Daigre, J. *et al.* (2024) Preclinical evaluation of novel folate receptor 1-directed CAR T cells for ovarian cancer. Cancers 16: 333. *https://doi.org/10.3390/cancers16020333*

Pecher, A. C. *et al.* (2023) CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329: 2154–2162. *https://doi.org/10.1001/jama.2023.8753*

Nicod, C. *et al.* (2023) CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. Curr. Res. Transl. Med. 71:103385. *https://doi.org/10.1016/j.retram.2023.103385*

Mehra, V. *et al.* (2023) AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival. J. Immunother. Cancer 11: e007002. *https://doi.org/10.1136/jitc-2023-007002*

Machietto, R. *et al.* (2023) Chimeric antigen receptor T cell manufacturing on an automated cell processor. J. Vis. Exp. 18. *https://doi.org/10.3791/65488*

Zurko, J. C. *et al.* (2022) Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. Cytotherapy 24: 767–773. *https://doi.org/10.1016/j.jcyt.2022.03.011*

Palani, H. K. *et al.* (2023) Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: Real-world experience and cost analysis in India. Bone Marrow Transplant. 58: 160–167.
https://doi.org/10.1038/s41409-022-01866-5

Glienke, W. *et al.* (2022) GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD2 and releasing inducible IL-18. Front. Immunol. 13: 839783.
https://doi.org/10.3389/fimmu.2022.839783

Joedicke, J. *et al.* (2022) Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages. Mol. Ther. Methods Clin. Dev. 24: 181–198.
https://doi.org/10.1016/j.omtm.2021.12.005

Majzner, R. *et al.* (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603: 934–941.
https://doi.org/10.1038/s41586-022-04489-4

Song, H. *et al.* (2022) Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies. Int. Rev. Immunol. 41: 638–648.
https://doi.org/10.1080/08830185.2022.2067154

Wang, X. *et al.* (2022) Large-scale manufacturing and characterization of CMV-CD19CAR T cells. J. Immunother. Cancer 10: e003461.
https://doi.org/10.1136/jitc-2021-003461

Palen, K. *et al.* (2021) Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: Time for a collect-and-freeze model? Cytotherapy 23: 985–990.
https://doi.org/10.1016/j.jcyt.2021.07.015

Bozza, M. *et al.* (2021) A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. Sci. Adv. 7: eabf1333.
https://doi.org/10.1126/sciadv.abf1333

Arcangeli, S. *et al.* (2020) Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome diseasespecific T cell defects in cancer patients. Front. Immunol. 11: 1217.
https://doi.org/10.3389/fimmu.2020.01217

Li, H. *et al.* (2020) Preclinical development and clinical-scale manufacturing of HIV gag-specific, lentivirus-modified CD4 T cells for HIV functional cure. Mol. Ther. Methods Clin. Dev. 17: 1048–1060.
https://doi.org/10.1016/j.omtm.2020.04.024

Loff, S. *et al.* (2020) Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia. Mol. Ther. Oncolytics 17: 408–420.
https://doi.org/10.1016/j.omto.2020.04.009

Ran, T. *et al.* (2020) Cost of decentralized CAR T-cell production in an academic nonprofit setting. Int. J. Cancer. 147: 3438–3445.
https://doi.org/10.1002/ijc.33156

Aleksandrova, K. *et al.* (2019) Functionality and cell senescence of CD4/CD8-selected CD20 CAR T cells manufactured using the automated CliniMACS Prodigy Platform. Transfus. Med. Hemother. 46: 47–54.
https://doi.org/10.1159/000495772

Fernandez, L. *et al.* (2019) GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS Prodigy. Front. Immunol. 10: 2361.
https://doi.org/10.3389/fimmu.2019.02361

Vedvyas, Y. *et al.* (2019) Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. Sci. Rep. 9: 10634.
https://doi.org/10.1038/s41598-019-46938-7

Blaeschke, F. *et al.* (2018) Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. Cancer Immunol. Immunother. 67: 1053–1066.
https://doi.org/10.1007/s00262-018-2155-7

Castella, M. *et al.* (2018) Development of a novel anti-CD19 chimeric antigen receptor: A paradigm for an affordable CAR T cell production at academic institutions. Mol. Ther. Methods Clin. Dev. 12: 134–144.
https://doi.org/10.1016/j.omtm.2018.11.010

Zhang, W. *et al.* (2018) Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. Drug Des. Devel. Ther. 12: 3343–3356.
https://doi.org/10.2147/DDDT.S175113

Georgiadis, C. *et al.* (2018) Long terminal repeat CRISPR-CAR-coupled "Universal" T cells mediate potent anti-leukemic effects. Mol. Ther. 26: 1215–1227.
https://doi.org/10.1016/j.ymthe.2018.02.025

Zhu, F. *et al.* (2018) Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy 20: 394–406.
https://doi.org/10.1016/j.jcyt.2017.09.005

Lock, D. & Mockel-Tenbrinck, N. *et al.* (2017) Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum. Gene Ther. 28: 914–925.
https://doi.org/10.1089/hum.2017.111

Mock, U. *et al.* (2016) Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy. Cytotherapy 18: 1002–1011.
https://doi.org/10.1016/j.jcyt.2016.05.009

Priesner, C. *et al.* (2016) Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs. Hum. Gene Ther. 27: 860–869.
https://doi.org/10.1089/hum.2016.091



Miltenyi Biotec

Miltenyi Biotec provides products and services worldwide. Visit **www.miltenyibiotec.com/local** to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.
In the EU, the CliniMACS® System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated.
The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients.
The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans, the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.
CliniMACS, CliniMACS Prodigy, and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec B.V. & Co. KG and/or its affiliates in various countries worldwide. Copyright © 2025 Miltenyi Biotec and/or its affiliates. All rights reserved.

130-133-540.02